KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Gains from Sales and Divestitures (2019 - 2021)

Twist Bioscience (TWST) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $62000.0 as the latest value for Q4 2021.

  • On a quarterly basis, Gains from Sales and Divestitures rose 14.81% to $62000.0 in Q4 2021 year-over-year; TTM through Dec 2021 was $62000.0, a 14.81% increase, with the full-year FY2021 number at $237000.0, up 33.15% from a year prior.
  • Gains from Sales and Divestitures was $62000.0 for Q4 2021 at Twist Bioscience, down from $237000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $237000.0 in Q3 2021 to a low of $121.0 in Q1 2021.
  • A 3-year average of $96124.6 and a median of $62000.0 in 2021 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: surged 2125.0% in 2020, then crashed 99.9% in 2021.
  • Twist Bioscience's Gains from Sales and Divestitures stood at $8000.0 in 2019, then skyrocketed by 575.0% to $54000.0 in 2020, then increased by 14.81% to $62000.0 in 2021.
  • Per Business Quant, the three most recent readings for TWST's Gains from Sales and Divestitures are $62000.0 (Q4 2021), $237000.0 (Q3 2021), and $178000.0 (Q2 2021).